Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early rheumatoid arthritis.

Kate L Mitchell1, David S Pisetsky

  • 1Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC 27705, USA.

Current Opinion in Rheumatology
|April 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making Artificial Intelligence More Intelligent and Less Artificial for Rheumatology: A Vision for Empathy, Education, Equity, and Ethics.

Arthritis care & research·2026
Same author

The influence of nuclear antigen form on complement activation by systemic lupus erythematosus antinuclear antibody immune complexes determined by a novel immunocapture assay.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Z-GENIE: a user-friendly R/Shiny resource for predicting Z-DNA forming regions in DNA.

BMC genomics·2025
Same author

Pain in systemic lupus erythematosus: emerging insights and paradigms.

Nature reviews. Rheumatology·2025
Same author

DNA coronas resist nuclease degradation.

Biophysical journal·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Identifying prognostic markers and understanding aggressive treatment roles are key for managing rheumatoid arthritis (RA). Early intervention with disease-modifying antirheumatic drugs (DMARDs) can prevent joint damage and induce remission in RA patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Genetics

Background:

  • Rheumatoid arthritis (RA) is a chronic inflammatory condition requiring early intervention.
  • Diagnostic uncertainty and potential spontaneous remission complicate early treatment decisions.
  • Identifying prognostic markers is crucial for guiding therapy.

Purpose of the Study:

  • To identify prognostic markers for early rheumatoid arthritis.
  • To evaluate the role of aggressive treatment strategies in inducing remission.
  • To improve outcomes and prevent joint damage in RA patients.

Main Methods:

  • Review of recent research on genetic markers, serology (anti-citrullinated peptide antibodies), and radiographic techniques.
  • Analysis of clinical studies on combination therapy for RA.

Related Experiment Videos

Main Results:

  • Genetic markers predict rapid joint destruction.
  • Serology aids in RA diagnosis; radiography detects early synovitis and erosion.
  • Combination therapy, particularly methotrexate with biologics like TNF blockers, effectively reduces RA disease activity.

Conclusions:

  • Current treatments offer significant benefits for early RA.
  • Further research is needed for targeted therapy selection.
  • Identifying patient-specific responses to different agents is essential for optimizing RA management.